BioMarin Pharmaceutical (BMRN) Stock Analysis & AI Equity Report
BioMarin Pharmaceutical (BMRN) overview
BioMarin Pharmaceutical (BMRN) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 3,221m and operating profit of USD 409m; the year-end share price was 59.43 USD and market capitalisation was USD 11,428m. BioMarin Pharmaceutical is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get BioMarin Pharmaceutical's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About BioMarin Pharmaceutical
BioMarin develops and commercializes medicines for rare and genetically defined diseases. Its portfolio includes approved therapies and research programs spanning clinical and preclinical development. The company uses genetic and enzyme technologies in drug discovery and works to bring treatments to patients through its commercial operations and healthcare providers in multiple countries.
Generate the BioMarin Pharmaceutical report
BioMarin Pharmaceutical is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for BioMarin Pharmaceutical and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on BioMarin Pharmaceutical
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.